中东和非洲人类疫苗佐剂市场预测至 2030 年 - 区域分析 - 按类型（颗粒佐剂、乳液佐剂、组合佐剂及其他）、应用（流感、肝炎、人乳头瘤病毒 (HPV) 及其他）和最终用户（制药和生物技术公司、CMO 和 CRO 及其他）

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030

No. of Pages: 109    |    Report Code: BMIRE00030455    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Middle East & Africa Human Vaccine Adjuvants Market
Free Sample Buy Now
2022 年中东和非洲人类疫苗佐剂市场价值为 4918 万美元，预计到 2030 年将达到 1.1937 亿美元；预计 2022 年至 2030 年的复合年增长率为 11.7%。

慢性病患病率上升促进中东和非洲人类疫苗佐剂市场

慢性病患病率上升推动了对疫苗佐剂的需求。疫苗中添加佐剂以增强功效和人体的免疫反应。它们通过刺激更强烈和更持久的免疫反应来帮助提高疫苗的有效性。随着对预防和管理慢性病的疫苗的需求不断增长，对佐剂的需求也在增加。心血管疾病、癌症、糖尿病和呼吸系统疾病等慢性病在全球范围内呈上升趋势。根据世界卫生组织的数据，非传染性疾病相关死亡人数最多的是心血管疾病，每年造成 1700 万人死亡，其次是癌症、慢性呼吸道疾病和糖尿病（包括与肾脏相关的死亡）。此外，根据世界心脏联盟的数据，高胆固醇每年导致 440 万人死亡，而 24% 的心血管相关死亡可归因于高低密度脂蛋白 (LDL) 胆固醇。因此，慢性病负担的增加导致对可以预防或控制这些疾病的疫苗的需求不断增长。肝炎的患病率也在增加。肝炎疫苗中的佐剂旨在引发强大而持久的免疫力，特别是对标准疫苗制剂反应不佳的人群，例如患有潜在疾病或与年龄相关的免疫衰老的人群。根据世界卫生组织的数据，全世界有超过 3.5 亿人患有乙型或丙型肝炎。在所有类型的肝炎中，有几种可以通过接种疫苗预防。根据世界卫生组织的一项研究，到 2030 年，中低收入国家估计有 450 万人通过接种疫苗可以避免因肝炎而过早死亡。因此，慢性病的日益流行推动了中东和非洲人用疫苗佐剂市场的增长。

中东和非洲人用疫苗佐剂市场概览

沙特阿拉伯计划将 40% 的制药行业本地化，并减少对进口的依赖，作为其国家转型计划的一部分。在沙特阿拉伯，经济和社会变化导致久坐生活方式的转变，从而导致肥胖症患病率不断上升，代谢综合征预计也会上升。此外，患者缺乏疾病意识和对疾病传播的了解，这也增加了该国传染病的流行率。例如，根据 2023 年在 PubMed 上发表的一项研究“沙特阿拉伯和阿联酋的乙肝病毒感染：公共卫生挑战及其补救措施”，沙特阿拉伯即使在实施大规模疫苗接种计划后，在乙肝病毒治疗和管理方面仍面临严峻挑战。同样，根据 ICO/IARC 信息中心 2023 年关于 HPV 和癌症的报告，沙特阿拉伯有 1070 万 15 岁及以上的女性面临患 HPV 相关宫颈癌的风险。因此，阿联酋传染病的日益流行刺激了对人类疫苗佐剂的需求。近年来，沙特阿拉伯王国在医疗保健和制药领域投入了大量资金，旨在提高国内生产、研发能力。这一战略重点为潜在增长奠定了基础，影响了中东和非洲的人类疫苗佐剂市场。在沙特阿拉伯，法赫德国王医疗城、费萨尔国王专科医院及研究中心和卫生部等机构积极参与推动医疗保健研究，包括与疫苗和佐剂相关的研究。对研究设施和医疗基础设施的此类投资表明了它们致力于为全球疫苗领域做出贡献。预计它还将为佐剂研究和开发进步铺平道路。

中东和非洲人用疫苗佐剂市场收入及预测至 2030 年（百万美元）

中东和非洲人用疫苗佐剂市场细分

中东和非洲人用疫苗佐剂市场分为类型、应用、最终用户和国家。

根据类型，中东和非洲人用疫苗佐剂市场分为颗粒佐剂、乳剂佐剂、组合佐剂和其他。颗粒佐剂部分在 2022 年占据了最大的市场份额。

就应用而言，中东和非洲人用疫苗佐剂市场分为流感、肝炎、人乳头瘤病毒 (HPV) 等。流感部分在 2022 年占据了最大的市场份额。

按最终用户划分，中东和非洲人用疫苗佐剂市场细分为制药和生物技术公司、CMO 和 CRO 等。制药和生物技术公司部分在 2022 年占据了最大的市场份额。

按国家/地区划分，中东和非洲人用疫苗佐剂市场细分为沙特阿拉伯、南非、阿联酋和中东及非洲其他地区。 2022 年，沙特阿拉伯占据了中东和非洲人类疫苗佐剂市场的主导份额。

诺华股份公司 (Novartis AG)、CSL 有限公司、Seppic SA、Croda International Plc、Novavax Inc 和 Phibro Animal Health Corp 是中东和非洲人类疫苗佐剂市场的一些领先公司。

Middle East & Africa Human Vaccine Adjuvants Strategic Insights

Strategic insights for Middle East & Africa Human Vaccine Adjuvants involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/middle-east-and-africa-human-vaccine-adjuvants-market-strategic-framework.webp
Get more information on this report

Middle East & Africa Human Vaccine Adjuvants Report Scope

Report Attribute Details
Market size in 2022 US$ 49.18 Million
Market Size by 2030 US$ 119.37 Million
Global CAGR (2022 - 2030) 11.7%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 类型
  • 颗粒佐剂
  • 乳化佐剂
  • 组合佐剂
By 应用
  • 流感
  • 肝炎
  • 人乳头瘤病毒
By 最终用户
  • 制药和生物技术公司
  • CMO 和 CRO
Regions and Countries Covered 中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
Market leaders and key company profiles
  • Novartis AG
  • CSL Ltd
  • Seppic SA
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp
    		•
    Get more information on this report

    Middle East & Africa Human Vaccine Adjuvants Regional Insights

    The regional scope of Middle East & Africa Human Vaccine Adjuvants refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/middle-east-and-africa-human-vaccine-adjuvants-market-geography.webp
    Get more information on this report
    Identical Market Reports with other Region/Countries

    The List of Companies - Middle East & Africa Human Vaccine Adjuvants Market

    1. Novartis AG 
    2. CSL Ltd 
    3. Seppic SA 
    4. Croda International Plc 
    5. Novavax Inc 
    6. Phibro Animal Health Corp 

    Frequently Asked Questions
    How big is the Middle East & Africa Human Vaccine Adjuvants Market?

    The Middle East & Africa Human Vaccine Adjuvants Market is valued at US$ 49.18 Million in 2022, it is projected to reach US$ 119.37 Million by 2030.

    What is the CAGR for Middle East & Africa Human Vaccine Adjuvants Market by (2022 - 2030)?

    As per our report Middle East & Africa Human Vaccine Adjuvants Market, the market size is valued at US$ 49.18 Million in 2022, projecting it to reach US$ 119.37 Million by 2030. This translates to a CAGR of approximately 11.7% during the forecast period.

    What segments are covered in this report?

    The Middle East & Africa Human Vaccine Adjuvants Market report typically cover these key segments-

  • 类型 (颗粒佐剂, 乳化佐剂, 组合佐剂)
  • 应用 (流感, 肝炎, 人乳头瘤病毒)
  • 最终用户 (制药和生物技术公司, CMO 和 CRO)

    • What is the historic period, base year, and forecast period taken for Middle East & Africa Human Vaccine Adjuvants Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Human Vaccine Adjuvants Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
    • Who are the major players in Middle East & Africa Human Vaccine Adjuvants Market?

    The Middle East & Africa Human Vaccine Adjuvants Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Novartis AG
  • CSL Ltd
  • Seppic SA
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp
    • Who should buy this report?

    The Middle East & Africa Human Vaccine Adjuvants Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Middle East & Africa Human Vaccine Adjuvants Market value chain can benefit from the information contained in a comprehensive market report.

    middle-east-and-africa-human-vaccine-adjuvants-market